NeoPlus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma.

被引：0
作者：
Mao, Lili
Si, Lu
Dai, Jie
Bai, Xue
Li, Caili
Wei, Xiaoting
Cui, Chuanliang
Chi, Zhihong
Sheng, Xinan
Tang, Bixia
Lian, Bin
Wang, Xuan
Yan, Xieqiao
Zhou, Li
Kong, Yan
Wu, Xiaowen
Li, Siming
Li, Juan
Guo, Jun
机构：
[1] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Melanoma & Sarcoma Oncol, Beijing, Peoples R China
[2] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Melanoma & Sarcoma, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
中国国家自然科学基金;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9514
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.
    Rahma, Osama E.
    Katz, Matthew H. G.
    Wolpin, Brian M.
    Dias-Costa, Andressa
    Nowak, Jonathan
    Rodig, Scott J.
    Dougan, Stephanie
    Bekaii-Saab, Tanios S.
    Stucky, Chee-Chee H.
    Elias, Rawad
    Petroni, Gina R.
    Bauer, Todd W.
    Slingluff, Craig L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors
    Strosberg, J.
    Al-Toubah, T.
    Morse, B.
    Haider, M.
    Valone, T.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 237 - 237
  • [23] Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors
    Al-Toubah, T.
    Schell, M. J.
    Morse, B.
    Haider, M.
    Valone, T.
    Strosberg, J.
    ESMO OPEN, 2024, 9 (04)
  • [24] Neoadjuvant toripalimab plus axitinib in patients (pts) with resectable mucosal melanoma (MuM): Updated findings of a single-arm, phase II trial
    Cui, C-L.
    Li, Z.
    Wu, N.
    Li, M.
    Chen, X.
    Zheng, H.
    Gao, M.
    Wang, D.
    Lian, B.
    Wang, X.
    Tian, H.
    Si, L.
    Chi, Z.
    Sheng, X.
    Lai, Y.
    Sun, T.
    Zhang, Q.
    Kong, Y.
    Guo, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S908 - S908
  • [25] Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial
    Long, Georgina V.
    Carlino, Matteo S.
    Au-Yeung, George
    Spillane, Andrew J.
    Shannon, Kerwin F.
    Gyorki, David E.
    Hsiao, Edward
    Kapoor, Rony
    Thompson, Jake R.
    Batula, Iris
    Howle, Julie
    Ch'ng, Sydney
    Gonzalez, Maria
    Saw, Robyn P. M.
    Pennington, Thomas E.
    Lo, Serigne N.
    Scolyer, Richard A.
    Menzies, Alexander M.
    NATURE MEDICINE, 2024, 30 (09) : 2540 - 2548
  • [26] Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
    Davar, Diwakar
    Morrison, Robert M.
    Dzutsev, Amiran K.
    Karunamurthy, Arivarasan
    Chauvin, Joe-Marc
    Amatore, Florent
    Deutsch, Julie S.
    Das Neves, Rodrigo X.
    Rodrigues, Richard R.
    McCulloch, John A.
    Wang, Hong
    Hartman, Douglas J.
    Badger, Jonathan H.
    Fernandes, Miriam R.
    Bai, Yulong
    Sun, Jie
    Cole, Alicia M.
    Aggarwal, Poonam
    Fang, Jennifer R.
    Deitrick, Christopher
    Bao, Riyue
    Duvvuri, Umamaheswar
    Sridharan, Shaum S.
    Kim, Seungwon W.
    Choudry, Haroon A.
    Holtzman, Matthew P.
    Pingpank, James F.
    O'Toole, James Patrick
    DeBlasio, Richelle
    Jin, Yang
    Ding, Quanquan
    Gao, Wentao
    Groetsch, Christopher
    Pagliano, Ornella
    Rose, Amy
    Urban, Corey
    Singh, Jagjit
    Divarkar, Prajan
    Mauro, David
    Bobilev, Dmitri
    Wooldridge, James
    Krieg, Arthur M.
    Fury, Matthew G.
    Whiteaker, Jeffrey R.
    Zhao, Lei
    Paulovich, Amanda G.
    Najjar, Yana G.
    Luke, Jason J.
    Kirkwood, John M.
    Taube, Janis M.
    CANCER CELL, 2024, 42 (11) : 1898 - +
  • [27] A phase II study of ABT-510 for the treatment of metastatic melanoma.
    Markovic, S.
    Suman, V.
    Rao, R.
    Creagan, E.
    Maples, W.
    Kaur, J.
    McWilliams, R.
    Allred, J.
    Pitot, H.
    Croghan, G.
    Humerickhouse, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 463S - 463S
  • [28] A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC
    Lemmon, Christopher A.
    Videtic, Gregory M. M.
    Murthy, Sudish
    Stephans, Kevin L.
    Shapiro, Marc
    Ahmad, Usman
    Raymond, Daniel
    Velcheti, Vamsidhar
    Bribriesco, Alejandro
    Jia, Xuefei
    Stevenson, James
    Pennell, Nathan A.
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (07):
  • [29] Observational study with lenvatinib and pembrolizumab in heavily pretreated patients with metastatic melanoma
    Pasek, Marek
    Marques, Emanuel
    Svec, Jiri
    Arenberger, Petr
    Arenbergerova, Monika
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2024, 63 (09) : e219 - e220
  • [30] A phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with advanced melanoma.
    Shaikh, Saba
    Zang, Yan
    Hanmer, Janel
    Wang, Hong
    Lin, Yan
    Davar, Diwakar
    Zarour, Hassane M.
    Kirkwood, John M.
    Najjar, Yana G.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345